Jubiant Therapeutics gets USFDA clearance for JBI-802 to treat solid tumours
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies
The brand is now available pan-India through their distribution partner
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
Entacapone tablets USP, 200 mg have an estimated market size of US$ 10.5 million for twelve months ending September 2021, according to IQVIA
The test kit is compatible with all standard Real-Time PCR machines with a test run time of 85 minutes. The result turnaround time, including sample collection and RNA extraction, is 130 minutes
He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management
Biogen paid Ionis a US $ 60 million one-time upfront payment
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Subscribe To Our Newsletter & Stay Updated